You are here
Sunday, May 18, 2014
Common treatment for patients with chronic, progressive lung disease found to be ineffective
A drug used to treat patients with mild to moderate lung damage from the disease idiopathic pulmonary fibrosis (IPF) is no better than placebo for preserving lung function, according to a study supported by the National Institutes of Health.
The finding is in the final report of a clinical trial called Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis (PANTHER-IPF). It will be published May 23 in the New England Journal of Medicine.
Previous studies suggested that therapies combining N-acetylcysteine, or NAC, with immunosuppressive and anti-inflammatory drugs could slow progression of the disease. IPF affects about 200,000 people in the United States, only half of whom survive more than 2-3 years from initial diagnosis.
“IPF is a devastating disease,” said James Kiley, Ph.D., director of the Division of Lung Diseases at the NIH’s National Heart, Lung, and Blood Institute (NHLBI). “While it is disappointing that NAC was ineffective in preserving lung function in IPF, these are the kind of high-quality data that patients and their caregivers need to make informed decisions.”
Among other measures, researchers relied on forced vital capacity (FVC) to assess changes in lung function. FVC is the total amount of air a person can exhale after taking the deepest breath possible. During 60 weeks of follow-up, the study found no statistically significant difference in FVC declines, IPF symptom flare-ups, deaths, or hospitalizations between patients treated with NAC and those treated with placebo.
“We have made major strides in understanding the biology and clinical implications of pulmonary fibrosis,” said Fernando J. Martinez, M.D., executive vice chair of medicine at Weill Cornell Medical College, New York City, and an author of the study. “As a result, there is tremendous hope for therapeutic options on the horizon.”
IPF, an incurable disease characterized by buildup of fibrous scar tissue within the lungs, causes progressively worsening shortness of breath, coughing, chest pain, and fatigue.
Martinez co-led the research with Ganesh Raghu, M.D., professor of medicine and director of the University of Washington Center for Interstitial Lung Diseases.
Additional authors who wrote the manuscript for the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) are Joao A. de Andrade, M.D., associate professor of medicine and director of the University of Alabama at Birmingham Interstitial Lung Disease Program; Kevin J. Anstrom, Ph.D., associate professor of bioinformatics and statistics and member in the Duke Clinical Research Institute, Durham, North Carolina; and Talmadge E. King Jr., M.D., professor and chair of the department of medicine at the University of California, San Francisco.
PANTHER-IPF originally was designed as a three-arm clinical trial to compare a multidrug therapy of azathioprine, NAC, and prednisone with placebo and NAC alone.
NIH stopped the multidrug therapy arm of the trial in 2011 because of safety concerns. Interim results from that arm showed that compared with placebo, patients receiving the multidrug therapy had more deaths and more hospitalizations with no difference in lung function.
The study was funded through NHLBI grants U10HL080413 (data coordinating center), U10HL080274, U10HL080370, U10HL080371, U10HL080383, U10HL080411, U10HL080509, U10HL080510, U10HL080513, U10HL080543, U10HL080571, and U10HL080685 (clinical centers).
In addition to NIH funding, the Cowlin Family Fund at Chicago Community Trust provided financial support for this study. Zambon donated the NAC and matching placebo.
To schedule an interview with an NHLBI spokesperson, please contact the NHLBI Office of Communications at 301-496-4236 or email@example.com.
To schedule an interview with Fernando Martinez, please contact Ashley Paskalis at the Weill Cornell Medical College: 646-317-7378 firstname.lastname@example.org.
To schedule an interview with Ganesh Raghu, please contact Leila Gray at the University of Washington: 206-685-0381 or email@example.com.
About the National Heart, Lung, and Blood Institute (NHLBI): Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at http://www.nhlbi.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®
- Randomized Trial of N-acetylcysteine in Idiopathic Pulmonary Fibrosis (requires subscription): http://www.nejm.org/doi/full/10.1056/NEJMoa1401739
- Clinical Alert: Commonly Used Three-drug Regimen for Idiopathic Pulmonary Fibrosis Found Harmful: http://www.nlm.nih.gov/databases/alerts/2011_nhlbi_ifp.html
- PANTHER-IPF Questions and Answers: http://www.nhlbi.nih.gov/news/press-releases/supplement/questions-and-answers-panther-ipf-study.html